Financial Ratios

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE280.359.35 (+3.45 %)
PREV CLOSE ( ) 271.00
OPEN PRICE ( ) 275.30
BID PRICE (QTY) 280.35 (906)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 257539
TODAY'S LOW / HIGH ( )271.60 281.10
52 WK LOW / HIGH ( )217.5 307
NSE280.159 (+3.32 %)
PREV CLOSE( ) 271.15
OPEN PRICE ( ) 275.00
BID PRICE (QTY) 280.15 (14863)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 10392195
TODAY'S LOW / HIGH( ) 271.30 281.00
52 WK LOW / HIGH ( )217.5 307.1
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)23.720.722.343.646.31
   CEPS(Rs)24.701.623.204.453.92
   DPS(Rs)1.500.500.000.001.00
   Book NAV/Share(Rs)90.0166.6265.0462.11117.59
   Tax Rate(%)4.1338.3721.8220.4110.57
Margin Ratios
   Core EBITDA Margin(%)1.043.5215.3414.1811.75
   EBIT Margin(%)152.588.0617.7127.6323.83
   Pre Tax Margin(%)149.098.0417.6927.5723.69
   PAT Margin (%)142.934.9513.8321.9421.18
   Cash Profit Margin (%)148.7911.1818.9326.8726.35
Performance Ratios
   ROA(%)26.181.003.395.404.83
   ROE(%)30.291.093.686.015.51
   ROCE(%)29.841.744.657.466.06
   Asset Turnover(x)0.180.200.240.250.23
   Sales/Fixed Asset(x)0.880.841.050.900.76
   Working Capital/Sales(x)1.070.961.251.471.18
Efficiency Ratios
   Fixed Capital/Sales(x)1.141.200.951.111.32
   Receivable days124.41137.12106.04135.38167.78
   Inventory Days100.88102.1086.88122.68139.36
   Payable days160.73170.01204.20256.89283.20
Valuation Parameters
   PER(x)8.70466.53174.8974.4348.45
   PCE(x)8.35206.72127.7560.7777.90
   Price/Book(x)2.295.026.294.365.20
   Yield(%)0.730.150.000.000.16
   EV/Net Sales(x)12.7222.7523.8916.1420.37
   EV/Core EBITDA(x)85.97159.29104.7265.82113.96
   EV/EBIT(x)8.34282.32134.9058.4285.47
   EV/CE(x)2.084.846.134.265.06
   M Cap / Sales12.4323.1124.1816.3320.53
Growth Ratio
   Net Sales Growth(%)14.65-14.312.0111.35-26.19
   Core EBITDA Growth(%)18.77-46.34-5.1352.79-27.93
   EBIT Growth(%)2070.45-61.00-34.6229.0938.72
   PAT Growth(%)3208.25-69.30-35.7115.3358.62
   EPS Growth(%)3208.44-69.32-35.71-42.3358.62
Financial Stability Ratios
   Total Debt/Equity(x)0.120.010.000.000.01
   Current Ratio(x)3.684.073.942.862.53
   Quick Ratio(x)2.873.153.192.171.79
   Interest Cover(x)43.69350.25898.00457.83163.69
   Total Debt/Mcap(x)0.050.000.00

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.